SAN FRANCISCO — Daniel V.T. Catenacci, MD, a GI medical oncologist at the University of Chicago, discusses a novel gastric cancer prognostic model — the Yonsei University Gastric Cancer Prediction Tool — for which validation data was presented during a session he co-chaired at the Gastrointestinal Cancers Symposium.
This abstract introduced “a new nomogram for helping to determine patient risk of recurrence after surgery,” Catenacci said. “The nomogram adds to the current standard of determining risk [including] a number of … factors that we understand to be differential in prognosis.”
Disclosure: Catenacci reports honoraria from Amgen, Foundation Medicine, Genentech/Roche, Genmab, Lilly, OncoPlex Diagnostics and Taiho Pharmaceutical; consulting or advisory roles with Amgen, Genentech/Roche and OncoPlex Diagnostics; speakers’ bureau roles with Foundation Medicine, Lilly and OncoPlex Diagnostics; and research funding from Amgen, Genentech and OncoPlex Diagnostics.